Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Letter].
作者信息
Gupta-Werner Niodita, Goble Joseph, Slavcev Mary
机构信息
Johnson & Johnson, Horsham, PA, USA.
出版信息
Clinicoecon Outcomes Res. 2025 Jul 30;17:535-536. doi: 10.2147/CEOR.S550970. eCollection 2025.
Abstract
摘要
相似文献
1
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Letter].埃拉纳单抗治疗复发或难治性多发性骨髓瘤患者的经济影响[信函]
Clinicoecon Outcomes Res. 2025 Jul 30;17:535-536. doi: 10.2147/CEOR.S550970. eCollection 2025.
2
Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma.在英国，elranatamab与现实世界中针对三重暴露复发和难治性多发性骨髓瘤的治疗结果比较。
BMC Cancer. 2025 Jul 25;25(1):1219. doi: 10.1186/s12885-025-14624-9.
3
Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis.埃兰妥单抗用于伴有严重肾功能损害且需要血液透析的复发/难治性多发性骨髓瘤
Hematol Oncol. 2025 Jul;43(4):e70120. doi: 10.1002/hon.70120.
4
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain Amyloidosis.埃拉纳单抗治疗复发和/或难治性免疫球蛋白轻链淀粉样变性患者的安全性和有效性
Blood. 2025 Jul 25. doi: 10.1182/blood.2025028383.
5
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma.Elranatamab 疗效在 MagnetisMM-3 研究中与三药难治性多发性骨髓瘤真实世界对照臂的比较。
Future Oncol. 2024;20(17):1175-1189. doi: 10.2217/fon-2023-0995. Epub 2024 Feb 28.
6
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma.埃拉纳单抗治疗复发或难治性多发性骨髓瘤患者的经济影响
Clinicoecon Outcomes Res. 2025 Apr 8;17:289-302. doi: 10.2147/CEOR.S501404. eCollection 2025.
7
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma.引入新的治疗模式：埃拉纳单抗用于复发/难治性多发性骨髓瘤
Ann Pharmacother. 2025 May;59(5):473-484. doi: 10.1177/10600280241281742. Epub 2024 Oct 16.
8
Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States.美国复发或难治性多发性骨髓瘤中teclistamab和elranatamab的每位缓解者成本。
J Med Econ. 2025 Dec;28(1):910-920. doi: 10.1080/13696998.2025.2514909. Epub 2025 Jun 14.
9
Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies.复发或难治性多发性骨髓瘤患者且符合B细胞成熟抗原靶向治疗条件者的疾病负担
Future Oncol. 2025 Jul;21(17):2155-2165. doi: 10.1080/14796694.2025.2514399. Epub 2025 Jun 5.
10
Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain.与当前疗法相比，elranatamab治疗三重暴露、复发和难治性多发性骨髓瘤患者（包括西班牙的其他双特异性疗法和医生选择的治疗方法）的成本效益。
Oncol Ther. 2025 Apr 7. doi: 10.1007/s40487-025-00333-7.
本文引用的文献
1
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma.埃拉纳单抗治疗复发或难治性多发性骨髓瘤患者的经济影响
Clinicoecon Outcomes Res. 2025 Apr 8;17:289-302. doi: 10.2147/CEOR.S501404. eCollection 2025.
2
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.在1/2期MajesTEC-1研究中，COVID-19对复发/难治性多发性骨髓瘤患者使用替西帕单抗治疗结局的影响。
Blood Cancer J. 2024 Oct 21;14(1):186. doi: 10.1038/s41408-024-01160-1.
3
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.Elranatamab 治疗复发/难治性多发性骨髓瘤：MagnetisMM-3 期临床试验结果。
Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15.
4
Teclistamab in Relapsed or Refractory Multiple Myeloma.特卡昔单抗治疗复发或难治性多发性骨髓瘤。
N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5.
5
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.限制平均生存时间：替代风险比的方法，用于设计和分析具有时间事件结局的随机试验。
BMC Med Res Methodol. 2013 Dec 7;13:152. doi: 10.1186/1471-2288-13-152.
Zotero 插件